Literature DB >> 12428277

Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism.

A V Krylatov1, R V Uzhachenko, L N Maslov, N A Bernatskaya, A Makriyannis, R Mechoulam, R G Pertwee, O M Sal'nikova, J B Stefano, YuB Lishmanov.   

Abstract

Stimulation of cannabinoid receptors with endogenous cannabinoid anandamide and its enzyme-resistant analogue R-(+)-methanandamide improved cardiac resistance to arrhythmias induced by coronary occlusion and reperfusion. This antiarrhythmic effect was not associated with activation of NO synthase, since pretreatment with NG-nitro-L-arginine methyl ester had no effect on the incidence of ischemia/reperfusion-induced arrhythmias. Blockade of ATP-dependent K+ channels with glybenclamide did not abolish the antiarrhythmic effect of R-(+)-methanandamide. Antiarrhythmic activity of endogenous cannabinoids is probably associated with their direct effects on the myocardium.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12428277     DOI: 10.1023/a:1015574100494

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  11 in total

1.  Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes.

Authors:  Lina T Al Kury; Oleg I Voitychuk; Keun-Hang Susan Yang; Faisal T Thayyullathil; Petro Doroshenko; Ali M Ramez; Yaroslav M Shuba; Sehamuddin Galadari; Frank Christopher Howarth; Murat Oz
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

2.  Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.

Authors:  Sarah K Walsh; Claire Y Hepburn; Kathleen A Kane; Cherry L Wainwright
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 3.  The endocannabinoid system in cardiovascular function: novel insights and clinical implications.

Authors:  Salvador Sierra; Natasha Luquin; Judith Navarro-Otano
Journal:  Clin Auton Res       Date:  2017-12-08       Impact factor: 4.435

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 5.  Cardiovascular pharmacology of cannabinoids.

Authors:  P Pacher; S Bátkai; G Kunos
Journal:  Handb Exp Pharmacol       Date:  2005

6.  Electrophysiological effects of anandamide on rat myocardium.

Authors:  Qian Li; Hui-Jie Ma; Hao Zhang; Zhao Qi; Yue Guan; Yi Zhang
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

7.  Feasibility of targeting ischaemia-related ventricular arrhythmias by mimicry of endogenous protection by endocannabinoids.

Authors:  Ellen Andrag; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

8.  Harm reduction--the cannabis paradox.

Authors:  Robert Melamede
Journal:  Harm Reduct J       Date:  2005-09-22

Review 9.  Cannabinoids for Treating Cardiovascular Disorders: Putting Together a Complex Puzzle.

Authors:  Basma Ghazi Eid
Journal:  J Microsc Ultrastruct       Date:  2018 Oct-Dec

10.  Anandamide reduces intracellular Ca2+ concentration through suppression of Na+/Ca2+ exchanger current in rat cardiac myocytes.

Authors:  Qian Li; Na Cui; Yuanjie Du; Huijie Ma; Yi Zhang
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.